A single-center, Open label, single sequence, two-period, crossover study assessing the effect of Probenecid on the pharmacokinetics of Fevipiprant in healthy subjects
Latest Information Update: 05 Mar 2021
At a glance
- Drugs Fevipiprant (Primary) ; Probenecid
- Indications Atopic dermatitis; Chronic obstructive pulmonary disease; Nasal polyps
- Focus Pharmacokinetics
- Sponsors Novartis Pharma A.G.
Most Recent Events
- 05 Mar 2021 New trial record
- 25 Feb 2021 Results published in the Drug Metabolism and Disposition